Dr. Danielle Bruno

Dr. Danielle Bruno is a dedicated biomedical scientist passionate about academic research. She earned her BSc in Biomedical Sciences from UniFMU and completed both her master’s and PhD at the Federal University of São Paulo. Her master’s research utilized bioinformatics to study evolutionary models, while her PhD focused on basic Science, employing various molecular and cell biology techniques. Her interest in neuroscience grew through scientific events, leading her to join a major epilepsy research group at the University of Campinas (UNICAMP), where she gained practical experience in epilepsy and stroke clinics. She then became a postdoctoral researcher at the Molecular Genetics Laboratory, affiliated with the CEPID-BRAINN group.

Dr. Bruno specializes in multi-omics single-cell analysis and bioinformatics, focusing on epigenomics and gene expression. She has led high-throughput projects identifying circulating nucleic acid biomarkers, including cell-free microRNAs and DNA. At the University of Luxembourg, she developed innovative single-nuclei isolation protocols from brain tissues and performed advanced bioinformatics analyses in neuroepigenomics, specifically targeting mesial temporal lobe epilepsy. Her work has contributed to uncovering molecular mechanisms underlying epilepsy and advancing potential diagnostic and therapeutic approaches.

As a Marie Skłodowska-Curie Fellow at NeuroInsight, Dr. Danielle Bruno combines her expertise in neuroepigenomics with Dr. Cristina Reschke’s preclinical epilepsy research to comprehensively explore the role of epigenetic modifications at the single-cell level, particularly to circadian regulation in epileptogenesis. Her research focuses on developing single-nucleus isolation protocols from brain tissues of animal models, integrating multi-omics data to identify potential therapeutic targets. The ultimate goal is to design personalized therapeutic strategies for the treatment of pharmacoresistant epilepsy.